Results 201 to 210 of about 207,140 (324)
To: Delirium and sleep quality in the intensive care unit: the role of melatonin. [PDF]
Crit Care SciFinsterer J, Mehri S.
europepmc +1 more source
Annals of Neurology, EarlyView.Objective Myotonic dystrophy type 1 (DM1) is a highly variable, multisystemic genetic disorder caused by a CTG repeat expansion in the 3′ untranslated region of DMPK. Toxicity is exerted by repeat‐containing DMPK transcripts that sequester muscleblind‐like (MBNL) proteins and lead to deleterious yet predictable changes in alternative splicing.
Samuel T. Carrell +3 more
wiley +1 more source
Correction to: Optical coherence tomography with voxel-based morphometry: a new tool to unveil focal retinal neurodegeneration in multiple sclerosis. [PDF]
Brain Communeuropepmc +1 more source
To: Identification of distinct phenotypes and improving prognosis using metabolic biomarkers in COVID-19 patients. [PDF]
Crit Care SciScorza CA, Scorza FA, Finsterer J.
europepmc +1 more source
Annals of Neurology, EarlyView.Objective In Parkinson's disease (PD), the power of beta oscillations (± 13–30 hertz [Hz]) from subthalamic nucleus (STN) local field potentials (LFPs) is associated with motor symptoms. Beta power can be used for adaptive deep brain stimulation (aDBS) algorithms based upon symptom fluctuations.
Martijn G.J. de Neeling +8 more
wiley +1 more source
The Presence of the mtDNA4977 Deletion Does Not Necessarily Mean That It is Responsible for Major Depression [Letter]. [PDF]
Neuropsychiatr Dis TreatFinsterer J.
europepmc +1 more source
Annals of Neurology, EarlyView.Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono +3 more
wiley +1 more source